I Agree

We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms of Use.

PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Instem plc (INS)

Instem plc

Contract Win
RNS Number : 7449O
Instem plc
03 June 2020
 

Instem plc

 

("Instem" or the "Company")

 

Contract Win

 

Leading South Korean Contract Research Organisation adopts extensive suite of Preclinical Software and SEND Management Solutions

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that it has won a contract with Biotoxtech, a prominent non-clinical Contract Research Organization in South Korea. The contract is worth approximately $1 million, the majority of which will be recognised as revenue in 2020 and the balance in 2021.

 

Instem will provide a comprehensive package of preclinical data collection, analysis and regulatory submissions management solutions to automate and optimize study related processes at Biotoxtech's R&D facility in South Korea's North Chungcheong Province. Founded in 2000, Biotoxtech operates the largest R&D facility within South Korea and was the first in the region to receive certifications for Good Laboratory Practices by international regulators, including the US Food & Drug Administration.

The contract was awarded following a detailed competitive evaluation, in which Instem was recognized by the client as the global leader in the field of non-clinical IT solutions and the architect of the world's leading technology for the creation of SEND submissions.

 

Phil Reason, CEO of Instem plc, said: "We are delighted with our latest contract win, which further demonstrates our ability to build on the strong momentum achieved last year and provides additional visibility over this year's targets. South Korea has been investing heavily in its pharmaceutical R&D capabilities and has become a significant player on the global stage. We continue to have a strong footprint in the Asia-Pacific region and are working hard to ensure that we maintain our world leading market position - especially in the current climate."

 

For further information, please contact:

 

Instem plc

Via Walbrook

Phil Reason, CEO

 

Nigel Goldsmith, CFO

 

 

 

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Peter Steel

Rachel Hayes

 

 

 

 

Walbrook Financial PR

+44 (0) 20 7933 8780

Tom Cooper

instem@walbrookpr.com

Nick Rome

Nicholas Johnson

 

 

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

 

Instem solutions are in use by over 500 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

 

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

 

To learn more about Instem solutions and its mission, please visit  www.instem.com

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAKKBBQFBKDKAK
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close